酿酒酵母作为抗奶牛乳腺炎疫苗接种平台
奶牛乳腺炎对乳业影响重大,现有疫苗因难以触发强细胞免疫而效果有限。本研究结合体外、离体和体内方法,评估酿酒酵母作为新型抗奶牛乳腺炎疫苗平台的潜力。结果表明酿酒酵母对奶牛肌内和乳内免疫安全,但接种仅引起针对酵母平台的IFNγ和IL-17应答显著升高,而未针对疫苗抗原,提示需平衡酵母抗原的免疫优势。
要点
- 酿酒酵母对奶牛肌内和乳内免疫安全。
- 接种后针对酵母平台的IFNγ和IL-17应答显著升高。
- 针对疫苗抗原的应答未显著升高。
核心结论
- 酿酒酵母可作为抗奶牛乳腺炎疫苗平台且对奶牛肌内和乳内免疫安全,但需策略平衡酵母抗原免疫优势以开发成功候选疫苗。
研究设计与样本
- 研究结合体外、离体和体内方法评估酿酒酵母作为抗奶牛乳腺炎疫苗平台的潜力。
主要发现
- 酿酒酵母对奶牛肌内和乳内免疫安全。
- 接种后针对酵母平台的IFNγ和IL-17应答显著升高,但针对疫苗抗原的应答未显著升高。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Mastitis is a major issue for the dairy industry. Despite multiple attempts, the efficacy of available mastitis vaccines is limited and this has been attributed to their incapacity to trigger robust cell-mediated immunity. Yeasts have recently been identified as promising antigen vectors capable of inducing T-cell responses, surpassing the antibody-biased mechanisms elicited by conventional adjuvanted vaccines. In this study, we combine in vitro, ex vivo, and in vivo approaches to evaluate the potential of the yeast Saccharomyces cerevisiae as a platform for novel vaccines against bovine mastitis. We demonstrate that S. cerevisiae is safe for intramuscular and intramammary immunisation in dairy cows. Vaccination resulted in a significant increase of IFNγ and IL-17 responses against the yeast platform but not against the vaccine antigen. These observations highlight that strategies to counterbalance the immunodominance of S. cerevisiae antigens are necessary for the development of successful vaccine candidates.
引用
- Danzelle C, Cunha P, Noleto PG, et al. Saccharomyces cerevisiae as a platform for vaccination against bovine mastitis. Vaccine. 2024. PMID: 39326211. doi:10.1016/j.vaccine.2024.126385
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。